Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-04-24
2007-04-24
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S139100, C435S007100, C530S387900, C530S388220
Reexamination Certificate
active
10174293
ABSTRACT:
The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine receptor Bonzo (also referred to as STRL33, TYMSTR, HBMBU14 and CXCR6) and blocks the binding of a ligand (e.g., SExCkine (also referred to as chemokine alpha-5 and CXCL16) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to Bonzo and inhibit the binding of a ligand (e.g., SExCkine) and/or modulate a function of Bonzo. The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine SExCkine (also referred to as chemokine alpha-5) and inhibit binding of SExCkine to receptor (e.g., Bonzo). The invention also relates to targeting molecules which contain a first binding moiety which binds to mammalian Bonzo and a second binding moiety which binds to a molecule expressed on the surface of a target cell. The invention also relates to a method of promoting and/or effectuating the interaction of a Bonzo+cell and a target cell. The invention further relates to a method of modulating a function of Bonzo, and to the use of the antibodies, antigen-binding fragments, targeting molecules and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
REFERENCES:
patent: 5739103 (1998-04-01), Rollins et al.
patent: 5767260 (1998-06-01), Whitlow et al.
patent: 5824504 (1998-10-01), Elshourbagy et al.
patent: 5824782 (1998-10-01), Hölzer et al.
patent: 5889157 (1999-03-01), Pastan et al.
patent: 5948647 (1999-09-01), Ring
patent: 5985276 (1999-11-01), Lindhofer et al.
patent: 6037454 (2000-03-01), Jardieu et al.
patent: 6232084 (2001-05-01), MacPhee et al.
patent: 6251582 (2001-06-01), Littman et al.
patent: 6319675 (2001-11-01), Briskin et al.
patent: 2002/0076694 (2002-06-01), Littman et al.
patent: 0834563 (1998-04-01), None
patent: WO 98/44098 (1998-10-01), None
patent: WO 99/03888 (1999-01-01), None
patent: WO 99/12968 (1999-03-01), None
patent: WO 99/27078 (1999-06-01), None
patent: WO 99/50670 (1999-10-01), None
patent: WO 01/64752 (2001-09-01), None
Yoshimura et al. (2003). Negative regulation of cytokine signaling influences inflammation. Current Opinion in Immunology. 15:704-708.
Choy et al. (2001). Ctyokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344(12):907-916.
Brussel, A., et al., “Sequences and Predicted Structures of Chimpanzee STRL33 (Bonzo) and gpr15 (BOB),”Aids Res. Hum. Retroviruses15(14):1315-1319 (1999).
Lu, P.H. and R.S. Negrin, “A Novel Population of Expanded CD3+CD56+Cells Derived from T Cells with PotentIn VivoAntitumor Activity in Mice with Severe Combined Immunodeficiency,”J. Immunol. 153(4) :1687-1696 (1994).
Liao, F. et al., “STRL33, a Novel Chemokine Receptor-like Protein, Functions as a Fusion Cofactor for Both Macrophage-tropic and T Cell Line-tropic HIV-1,”J. Exp. Med. 185(11): 2015-2023 (1997).
Clapham, P.R. and R.A. Weiss, “Spoilt for Choice of Co-Receptors,”Nature 388: 230-231 (1997).
Alkhatib, G. et al., “A New SIV Co-receptor, STRL33,”Nature 388: 238 (1997).
Scarlatti, G. et al., “In VivoEvolution of HIV-1 Co-receptor Usage and Sensitivity to Chemokine-Mediated Suppression,”Nature Medicine 3(11): 1259-1265 (1997).
Edinger, A.L. et al., “CD4-independent, CCR5-dependent Infection of Brain Capillary Endothelial Cells by a Neurovirulent Simian Immunodeficiency Virus Strain,”Proc. Natl. Acad. Sci., USA 94: 14742-14747 (1997).
Edinger, A.L. et al., “Use of GPR1, GPR15, and STRL33 as Coreceptors by Diverse Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus Envelope Proteins,”Virology 249(2): 367-378 (1998).
Mörner, A. et al., “Primary Human Immunodeficiency Virus Type 2 (HIV-2) Isolates, Like HIV-1 Isolates, Frequently Use CCR5 but Show Promiscuity in Coreceptor Usage,”J. Virol. 73(3): 2343-2349 (1999).
Zhang, Y-J. and J.P. Moore, “Will Multiple Coreceptors Need to be Targeted by Inhibitors of Human Immunodeficiency Virus Type 1 Entry?,”J. Virol. 73(4): 3443-3448 (1999).
Deng, H. et al., “Expression Cloning of New Receptors Used by Simian and Human Immunodeficiency Viruses,”Nature 388: 296-300 (1997).
Zhang, Y-J. et al. “Use of Coreceptors Other than CCR5 by Non-Syncytium-Inducing Adult and Pediatric Isolates of Human Immunodeficiency Virus Type 1 is RareIn Vitro,” J. Virol. 72(11): 9337-9344 (1998).
Littman, D.R., “Chemokine Receptors: Keys to AIDS Pathogenesis?,”Cell 93: 677-680 (1998).
Owen, S.M. et al., “Genetically Divergent Strains of Human Immunodeficiency Virus Type 2 Use Multiple Coreceptors for Viral Entry,”J. Virol. 72(7): 5425-5432 (1998).
Ponath, P.D. et al., “Molecular Cloning and Characterization of a Human Eotaxin Receptor Expressed Selectively on Eosinophils,”J. Exp. Med. 183: 2437-2448 (1996).
Wu, L. et al., “Discrete Steps in Binding and Signaling of Interleukin-8 with Its Receptor,”J. Biol. Chem. 271(49): 31202-31209 (1996).
Wu, L. et al., “CD4-Induced Interaction of Primary HIV-1 gp120 Glycoproteins with the Chemokine Receptor CCR-5,”Nature 384:179-183 (1996).
Loetscher, M. et al., “TYMSTR, A Putative Chemokine Receptor Selectively Expressed in Activated T Cells Exhibits HIV-1 Coreceptor Function,”Current Biology7(9):652-660 (1997).
Jin, Y. et al., “The Regulation of Phenotype and Function of Human Liver CD3+/CD56+Lymphocytes, and Cells That Also Co-Express CD8 by IL-2, IL-12 and Anti-CD3 Monoclonal Antibody,”Human Immunology 59: 352-362 (1998).
Goldman, L.A. et al., “Modifications of Vectors pEF-BOS, pcDNA1 and pcDNA3 Result in Improved Convenience and Expression,”Biotechniques21(6):1013-1015 (1996).
Sornasse, T. et al., “Differentiation and Stability of T Helper 1 and 2 Cells Derived from Naive Human Neonatal CD4+T Cells, Analyzed at the Single-cell Level,”J. Exp. Med. 184:473-483 (1996).
Wu, L., et al. “CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro,”J. Exp. Med. 185(9):1681-1691 (1997).
Yoshie, O., et al. “Novel Lymphocyte-Specific CC Chemokines and Their Receptors,”J. Leukoc. Biol., 62:634-644 (1997).
GenBank Accession No. AA290712, “zt18a10.r1 Soares Ovary Tumor NbHOTHomo sapienscDNA Clone IMAGE:713466 5′ , mRNA Sequence,” (1997) [online], [retrieved on Jul. 14, 1999]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov>.
GenBank Accession No. AA283690, “zt18a10.s1 Soares Ovary Tumor NbHOTHomo sapienscDNA Clone IMAGE:713466 3′ Similar to Contains Element LTR8 Repetitive Element; mRNA Sequence,” (1997) [online], [retrieved on Jul. 14, 1999]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov>.
GenBank Accession No. AI312518, “qp10a09.x1 NCI—CGAP—Kid5Homo sapienscDNA Clone IMAGE:1917592 3′ Similar to Contains Alu Repetitive Element; Contains Element MSR1 Repetitive Element; mRNA Sequence,” (1999) [online], [retrieved on Jul. 14, 1999]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov>.
GenBank Accession No. AA366329, “EST77447 Pancreas Tumor IIIHomo sapienscDNA 5′ End, mRNA Sequence,” (1997) [online], [retrieved on Jul. 14, 1999]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov>.
GenBank Accession No. AA146672, “zo33b12.r1 Stratagene Colon (#937204)Homo sapienscDNA Clone IMAGE:588671 5′ mRNA Sequence,” (1996) [online], [retrieved on Jul. 14, 1999]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov>.
GenBank Accession No. F14505, “SSC1C52 Porcine Small Intestine cDNA LibrarySus scrofacDNA, mRNA Sequence,” (1996) [online], [retrieved on Jul. 14, 1999]. Retrieved from the Internet: <URL:http://www.ncbi.n
Briskin Michael J.
Murphy Kristine E.
Wilbanks Alyson M.
Wu Lijun
Hamilton Brook Smith & Reynolds P.C.
Lockard Jon M
Millennium Pharmaceuticals Inc.
Saoud Christine J.
LandOfFree
Antibodies for “Bonzo” chemokine receptor and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies for “Bonzo” chemokine receptor and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies for “Bonzo” chemokine receptor and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3807488